Drugs / dezamizumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01777243 | May 2013 → Dec 2015 | amyloidosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03044353 | Jul 2017 → Jan 2019 | amyloidosis | GlaxoSmithKline | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03417830 Background | Apr → Jul 2018 | amyloidosis | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dezamizumab | “This residual SAP is a specific target for dezamizumab, a fully humanized monoclonal IgG1 anti-SAP antibody that triggers immunotherapeutic clearance of amyloid.” PMID 29298867 ↗ Jan 2018 |
| Known as | Anti - sap mab | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297966 ↗ |
| Known as | GSK2398852 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03417830 ↗ |
| Action | Inhibit | “Serum amyloid P-component inhibitor” CHEMBL4297966 ↗ |
| Modality | Monoclonal antibody | “dezamizumab, a fully humanized monoclonal IgG1 anti-SAP antibody” PMID 29298867 ↗ Jan 2018 |
| Route | Intravenous | “Subjects will be administered up to 490 mg of GSK2398852, IV.” NCT03417830 ↗ |
| Target | APCS | “Serum amyloid P-component inhibitor” CHEMBL4297966 ↗ |